|1.||Al-Abed, Yousef: 3 articles (08/2010 - 04/2007)|
|2.||Tracey, Kevin J: 3 articles (07/2009 - 05/2006)|
|3.||Yue, Ye: 2 articles (12/2015 - 01/2014)|
|4.||Liu, Ruoxi: 2 articles (12/2015 - 01/2014)|
|5.||Zhang, Peng: 2 articles (12/2015 - 01/2014)|
|6.||Hu, Yiping: 2 articles (12/2015 - 01/2014)|
|7.||Li, Jinchao: 2 articles (12/2015 - 01/2014)|
|8.||Cheng, Wenxiang: 2 articles (12/2015 - 01/2014)|
|9.||Yang, Huan: 2 articles (01/2014 - 07/2009)|
|10.||Rosas-Ballina, Mauricio: 2 articles (07/2009 - 04/2007)|
12/01/2015 - "The study aimed to analyze cytokine expression suppressed by GTS-21 with lipopolysaccharide (LPS)-induced inflammation in vitro and to gain insights into the role of Akt/NF-κB signaling pathway in this process. "
12/01/2015 - "These findings indicate that GTS-21 suppresses LPS-induced inflammation by inhibiting the Akt/NF-κB signal pathway through α7 nAChR. "
12/01/2015 - "GTS-21, a selective α7 nicotinic acetylcholine receptor agonist, has recently been established as a promising treatment for inflammation. "
10/01/2011 - "We evaluated the effects of stimulation of the cholinergic anti-inflammatory pathway with the selective partial α7 nicotinic acetylcholine receptor (α7nAChR) agonist GTS-21 on inflammation and lung injury induced by MV using clinically relevant ventilator settings. "
12/01/2007 - "However, GTS-21 did not influence the influx of neutrophils into bronchoalveolar lavage fluid elicited by LPS and increased the concentrations of the neutrophil-attracting chemokines cytokine-induced neutrophil chemoattractant and macrophage inflammatory protein 2. These data indicate that local administration of GTS-21 inhibits TNF-alpha release in the lung during LPS-induced inflammation."
|2.||Neurodegenerative Diseases (Neurodegenerative Disease)
12/01/1998 - "These results indicate that GTS-21 attenuates impairment of spatial cognitive deficit and progressive neuronal degeneration induced by 2VO and suggest that this compound is beneficial for the treatment of neurodegenerative diseases following chronic cerebral hypoperfusion."
07/01/1997 - "These results suggest that GTS-21 exhibits a protective action against the neuronal cell death in the parietal cortex and may have a beneficial effect on neurodegenerative disorders such as an Alzheimer-type disease."
03/01/2015 - "GTS-21, a selective agonist of alpha 7 nicotinic acetylcholine receptor, has been indicated to exert neuroprotective effects in the experimental animal models of neurodegenerative diseases. "
07/01/2011 - "Subjects received 150 mg GTS-21 (n = 7) or placebo (n = 7) orally three times per day during 3 days before endotoxin administration and on the day of the human endotoxemia experiment. "
07/01/2011 - "In the present work, we investigated the anti-inflammatory effects of GTS-21 on the innate immune response during experimental human endotoxemia. "
04/01/2007 - "GTS-21 (4 mg/kg) significantly inhibited serum tumor necrosis factor during endotoxemia and improved survival (p < .0001). "
04/01/2007 - "Mice were treated with GTS-21 (0.4 mg/kg or 4 mg/kg, intraperitoneally) or saline 30 mins before endotoxin (6 mg/kg, intraperitoneally), and serum tumor necrosis factor was analyzed 1.5 hrs after the onset of endotoxemia. "
04/01/2007 - "Selective alpha7-nicotinic acetylcholine receptor agonist GTS-21 improves survival in murine endotoxemia and severe sepsis."
|4.||Acute Lung Injury
01/01/2014 - "Our results indicate that GTS-21 is effective in improving bacterial clearance and reducing acute lung injury by enhancing macrophage function via inhibiting the release of nuclear HMGB1. "
01/01/2014 - "We found that systemic administration of 4 mg/kg GTS-21 significantly increased bacterial clearance, decreased acute lung injury and decreased accumulation of airway HMGB1. "
|5.||Tobacco Use Disorder (Nicotine Dependence)
|1.||Nicotinic Receptors (Nicotinic Acetylcholine Receptor)
|2.||HMGB1 Protein (HMG1)
|4.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|1.||Drug Therapy (Chemotherapy)
|2.||Mechanical Ventilators (Ventilator)